Train-of-four results and observed muscle movement in children during continuous neuromuscular blockade

Critical Care Nurse

Volumn 28, Issue 3, 2008, Pages 30-38

  Corso, Lisa ^a  

^a University of New Mexico School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROMUSCULAR BLOCKING AGENT;

AGE; ARTICLE; BLOOD; CHEMICALLY INDUCED DISORDER; CHILD; CLINICAL NURSING RESEARCH; DRUG EFFECT; DRUG MONITORING; ELECTROMYOGRAPHY; EVIDENCE BASED MEDICINE; FACIAL NERVE; FEMALE; HOSPITALIZATION; HUMAN; INFANT; INSTRUMENTATION; INTENSIVE CARE; MALE; METABOLIC CLEARANCE RATE; METHODOLOGY; MOVEMENT (PHYSIOLOGY); MUSCLE WEAKNESS; NEUROMUSCULAR BLOCKING; NEUROMUSCULAR SYNAPSE; NEWBORN; NURSING; NURSING ASSESSMENT; PREDICTION AND FORECASTING; PRESCHOOL CHILD; TIME; TOTAL QUALITY MANAGEMENT; ULNAR NERVE; UNITED STATES; VALIDATION STUDY;

AGE FACTORS; CHILD; CHILD, PRESCHOOL; CLINICAL NURSING RESEARCH; CRITICAL CARE; DRUG MONITORING; ELECTROMYOGRAPHY; EVIDENCE-BASED MEDICINE; FACIAL NERVE; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; METABOLIC CLEARANCE RATE; MOVEMENT; MUSCLE WEAKNESS; NEUROMUSCULAR BLOCKADE; NEUROMUSCULAR BLOCKING AGENTS; NEUROMUSCULAR JUNCTION; NEW MEXICO; NURSING ASSESSMENT; PREDICTIVE VALUE OF TESTS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TOTAL QUALITY MANAGEMENT; ULNAR NERVE;

EID: 50349088953     PISSN: 02795442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. McManus MC. Neuromuscular blockers in surgery and intensive care, part 1. Am J Health Syst Pharm. 2001;58:2287-2299.
2. Task Force of the American College of Critical Care Medicine (ACCM) of the Society of Critical Care Medicine (SCCM), the American Society of Health-system Pharmacists (ASHP), and the American College of Chest Physicians. Clinical practice guidelines for sustained neuromuscular blockade in the adult critically ill patient. Am J Health Syst Pharm. 2002;59:179-195.
3. Foster J, Kish S, Keenan C. National practice with assessment and monitoring of neuromuscular blockade. Crit Care Nurs Q. 2002;25:27-40.
4. McManus MC. Neuromuscular blockers in surgery and intensive care, part 2. Am J Health Syst Pharm. 2001;58:2381-2395.
5. Strange C, Vaughan L, Franklin C, Johnson J. Comparison of train-of-four and best clinical assessment during continuous paralysis. Am J Respir Crit Care Med. 1997; 156:1556-1561.
6. Luer J. Protocols for practice applying research at the bedside: sedation and neuromuscular blockade in patients with acute respiratory failure. Crit Care Nurs Q. 2002; 22:70-75.
7. Carroll P. A new way to monitor paralyzing drugs. RN. 2000;63(5):62-66.
8. Loyola R, Dreher HM. Management of pharmacologically induced neuromuscular blockade using peripheral nerve stimulation. Dimens Crit Care Nurs. 2003;22:157-164.
9. Murray MJ, Cowen J, DeBlock H, et al. Clinical practice guidelines for sustained neuromuscular blockade in the adult critically ill patient. Crit Care Med. 2002;30:142-156.
10. Reich DL, Hollinger I, Harrington DJ, Seiden HS, Chakravorti S, Cook DR. Comparison of cisatracurium and vecuronium by infusion in neonates and small infants after congenital heart surgery. Anesthesiology. 2004;101:1122-1127.
11. Bailey H, Kaplan LJ. Mechanical ventilation. In: Roberts JR, Hedges JR, eds. Clinical Procedures in Emergency Medicine. 4th ed. Philadelphia, PA: Saunders; 2004:146-170.
12. Jones SK. An algorithm for train-of-four monitoring in patients receiving continuous neuromuscular blocking agents. Dimens Crit Care Nurs. 2003;22:50-57.
13. Martin LD, Bratton SL, O'Roarke PP. Clinical uses and controversies of neuromuscular blocking agents in infants and children. Crit Care Med. 1999;27:1358-1368.
14. Arbour R. Mastering neuromuscular blockade, part 1. Nursing. November 2000;30: 32cc1.
15. Rapp HJ, Altenmueller CA, Waschke C. Neuromuscular recovery following rocuronium bromide single dose in infants. Paediatr Anaesth. 2004;14(4):329-335.
16. Odetola FO, Bhatt-Mehta V, Zahraa J, Moler FW, Custer JR. Cisatracurium infusion for neuromuscular blockade in the pediatric intensive care unit: a dose-finding study. Pediatr Crit Care Med. 2002;3:250-254.
17. Johnston MV. Development, structure, and function of the brain and neuromuscular systems. In: Fuhrman BP, Zimmerman J, eds. Pediatric Critical Care. 3rd ed. Philadelphia, PA: Mosby; 2006:767-779.
18. Cook RD. Neuromuscular blocking agents. In: Fuhrman BP, Zimmerman J, eds. Pediatric Critical Care. 3rd ed. Philadelphia, PA: Mosby; 2006:1729-1747.
19. Brandom B. Neuromuscular blocking drugs in pediatric patients. Anesth Analg. 2000; 90:S14-S18.
20. Nahata MC, Taketomo C. Basic concepts. In: Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: A Pathophysiologic Approach. 5th ed. New York, NY McGraw-Hill; 2002:69-77.
21. Saldien V, Vermeyen KM. Neuromuscular transmission monitoring in children. Paediatr Anaesth. 2004;14(4):289-292.
22. Brandom BW, Fine GF. Neuromuscular blocking drugs in pediatric anesthesia. Anesthesiol Clin North Am. 2002;20(1):45-58.
23. Biffl WL, Oka T, Cioffi WG. Surgical critical care. In: Townsend CM, Beauchamp RD, Evers BM, et al, eds. Sabiston Textbook of Surgery. 17th ed. Philadelphia, PA: Saunders; 2004:chap 24.
24. Eikermann M, Groeben H, Hüsing J, Peters J. Accelerometry of adductor pollicis muscle predicts recovery of respiratory function from neuromuscular blockade. Anesthesiology. 2003;98:1333-1337.
25. Rowlee SC. Monitoring neuromuscular blockade in the intensive care unit: the peripheral nerve stimulator. Heart Lung. 1999;28:352-362.
26. Viby-Mogensen J. Neuromuscular monitoring. In: Miller RD, ed. Miller's Anesthesia. 6th ed. Philadelphia, PA: Churchill Livingstone; 2005:1557-1570.
27. Arbour R. Mastering neuromuscular blockade, part 2. Nursing. December 2000;30: 32cc1.
28. Donati F. Neuromuscular blocking drugs for the new millennium: current practice, future trends-comparative pharmacology of neuromuscular blocking drugs. Anesth Analg. 2000;90(5 suppl):S2-S6.
29. Peña O, Prestjohn S, Guzzetta C. Agreement between muscle movement and peripheral nerve stimulation in critically ill pediatric patients receiving neuromuscular blocking agents. Heart Lung. 2000;29:309-318.
30. Denman WT, Kaplan RF, Goudsouzian NG, et al. Intramuscular rapacuronium in infants and children: a comparative multicenter study to confirm the efficacy and safety of the age-related tracheal intubating doses of intramuscular rapacuronium (ORG 9487) in two groups of pediatric subjects. Anesthesiology. 2001;94:3-7.
31. Baumann MH, McAlpin BW, Brown K, et al. A prospective randomized comparison of train-of-four monitoring and clinical assessment during continuous ICU cisatracurium paralysis. Chest. 2004;126:1267-1273.
32. Rudis MI, Sikora CA, Angus E, et al. A prospective, randomized, controlled evaluation of peripheral nerve stimulation versus standard clinical dosing of neuromuscular blocking agents in critically ill patients. Crit Care Med. 1997;25:575-583.
33. Sparr HJ, Beaufort TM, Fuchs-Buder T. Newer neuromuscular blocking agents: how do they compare with established agents? Drugs. 2001;61:919-942.
34. American College of Critical Care Medicine of the Society of Critical Care Medicine, American Society of Health-System Pharmacists, American College of Chest Physicians. Clinical practice guidelines for sustained neuromuscular blockade in the adult critically ill patient. Am J Health-Syst Pharm. 2002;59(2):179-195..